YBioF0003

YBioF0003 is a biologic drug candidate currently under development by Yerlika Biopharma for the treatment of osteoporosis. It is formulated for subcutaneous administration via a pen or autoinjector device. As of early 2024, the product is in the late stages of development, with three validation batches manufactured (Fill & Finish). Yerlika Biopharma expects to submit the regulatory dossier in the second quarter of 2025, with an anticipated market approval in 2026. While the specific molecular target has not been publicly disclosed by the manufacturer, the company's focus on biosimilar and technology-transfer biologics suggests it is likely a biosimilar version of an established osteoporosis therapy such as teriparatide or denosumab.